teaser
commun
focus
repurpos
clinic
approv
drug
promis
preclin
drug
candid
therapeut
develop
hostbas
antivir
agent
control
diseas
caus
coronaviru
influenza
viru
develop
highli
effect
antivir
agent
major
object
virolog
pharmaceut
drug
reposit
emerg
costeffect
timeeffici
altern
approach
tradit
drug
discoveri
develop
new
shift
focus
repurpos
clinic
approv
drug
promis
preclin
drug
candid
therapeut
develop
hostbas
antivir
agent
control
diseas
caus
coronaviru
influenza
viru
hostbas
antivir
agent
target
host
cellular
machineri
essenti
viral
infect
innat
immun
respons
interfer
viral
pathogenesi
review
discuss
current
knowledg
prospect
applic
challeng
repurpos
clinic
approv
preclin
studi
drug
newli
indic
antivir
therapeut
repurpos
approv
pharmaceut
drug
addit
applic
effici
altern
approach
advanc
therapeut
develop
costand
timeeffect
manner
advantag
repurpos
drug
exist
clinic
data
avail
afford
drug
patient
viral
infect
major
problem
morbid
mortal
anim
human
worldwid
therapeut
drug
approv
fda
treat
viral
infect
sinc
among
agent
ten
use
treat
hepat
c
viru
hcv
hiv
one
use
treat
cytomegaloviru
cmv
one
use
treat
influenza
viru
ifv
limit
avail
agent
control
viral
infect
emerg
resist
antivir
drug
underlin
urgent
need
effect
drug
manag
viral
infect
coronaviru
cov
ifv
see
glossari
full
list
abbrevi
two
major
respiratori
pathogen
caus
signific
morbid
mortal
anim
human
worldwid
cov
envelop
positivesens
rna
viru
classifi
coronavirida
famili
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
human
sar
mer
well
recogn
global
owe
outbreak
sever
infect
howev
lack
effect
therapeut
drug
control
sar
mer
mean
high
morbid
mortal
rate
reduc
addit
high
morbid
mortal
emerg
new
widehostrang
viral
member
potenti
domest
anim
adapt
difficulti
identifi
intermedi
host
major
concern
control
cov
infect
ifv
envelop
negativesens
rna
viru
associ
orthomyxovirida
famili
consist
ifva
b
c
genera
ifv
caus
season
outbreak
pandem
zoonot
diseas
vaccin
use
control
epidem
ifv
decad
antivir
agent
develop
target
ifv
ion
channel
amantadin
rimantadin
neuraminidas
zanamivir
oseltamivir
howev
use
agent
result
substanti
drug
resist
directact
antivir
daa
includ
vaccin
therapeut
agent
develop
directli
target
specif
viral
compon
howev
concern
approach
includ
ineffect
control
viral
infect
resist
daa
result
mutationassoci
variat
evolv
new
viral
variant
thu
therapeut
target
host
cellular
machineri
essenti
viral
infect
consid
develop
broadspectrum
agent
overcom
viral
variat
drug
resist
hosttarget
antivir
hta
design
target
specif
step
viral
infect
includ
viral
bind
host
cell
viral
entri
host
cell
viral
replic
viral
bud
exampl
fdaapprov
receptor
antagonist
maraviroc
mvc
effect
inhibit
entri
cell
treatment
human
monoclon
antibodi
ibalizuman
block
entri
cell
noncompetit
bind
show
patient
viral
load
copi
per
millilit
respect
week
howev
unclear
sideeffect
result
longterm
use
hta
review
discuss
progress
challeng
repurpos
clinic
approv
preclin
promis
therapeut
hta
target
viral
entri
viral
replic
innat
immun
respons
treat
cov
ifv
infect
entri
cov
ifv
host
cell
reli
bind
viral
particl
cellsurfac
receptor
endocytosi
virusreceptor
complex
fig
endosom
pathway
initi
fusion
viral
envelop
host
cell
membran
deliv
viral
nucleocapsid
cell
cov
also
enter
cell
via
nonendosom
pathway
thu
endosom
nonendosom
pathway
consid
target
develop
therapeut
drug
block
viral
entri
host
cell
depict
fig
promis
drug
list
tabl
cov
entri
requir
host
proteas
cleav
viral
trimer
transmembran
spike
glycoprotein
fig
cleavag
involv
cystein
proteas
cathepsin
l
endosom
pathway
host
transmembran
serin
proteas
nonendosom
pathway
ifv
entri
requir
envelop
fusion
host
membran
via
viral
hemagglutinin
ha
follow
proteolyt
cleavag
ha
also
hat
initi
endocytosi
thu
host
proteas
endosom
nonendosom
pathway
target
block
viral
entri
host
cell
activ
glycoprotein
sarscov
merscov
viral
entri
plasma
membran
camostat
synthet
lowmolecularweight
serin
proteas
inhibitor
use
treat
human
dyspepsia
associ
mild
pancreat
diseas
inhibit
camostat
result
reduct
merscov
product
human
bronchial
submucos
glandderiv
cell
camostat
also
effect
protect
mice
sarscov
infect
treatment
human
tracheal
epitheli
hte
cell
camostat
significantli
reduc
infect
virus
nafamostat
fdaapprov
serin
proteas
inhibitor
treat
pancreat
dissemin
intravascular
coagul
treatment
human
airway
epitheli
cell
nafamostat
block
merscov
infect
inhibit
result
signific
reduct
viral
product
ec
bhh
alreadi
approv
fda
ingredi
mucolyt
cough
suppress
like
develop
treat
cov
ifv
infect
cathepsin
import
role
cov
entri
cathepsin
l
b
serv
target
antivir
agent
vinylsulfon
irrevers
cystein
proteas
inhibitor
use
control
variou
parasit
infect
schistosomiasi
reportedli
effect
control
cathepsinmedi
viral
entri
includ
sarscov
nipah
viru
paramyxoviru
ebola
viru
filoviru
howev
treatment
fail
result
statist
signific
reduct
mortal
induc
sarscov
anim
cov
ifv
enter
host
cell
via
phand
receptormedi
endocytosi
involv
clathrinand
caveolaedepend
independ
endocyt
pathway
ifv
also
util
macropinocytosi
altern
entri
pathway
acid
lateendosom
compart
chlorpromazin
cpz
inhibitor
clathrindepend
endocytosi
first
antipsi
scheme
target
cov
ifv
infect
hostbas
repurpos
drug
cov
entri
cell
reli
either
nonendosom
pathway
endosom
pathway
involv
host
proteas
host
adapt
protein
clathrin
respect
ifv
entri
util
endosom
pathway
macropinocyt
pathway
pathway
render
releas
vrna
cytoplasm
follow
import
vrna
nucleu
viral
replic
host
protein
kinas
raf
mek
erk
cdk
import
role
regul
transcript
translat
variou
stage
viral
replic
cov
ifv
util
host
eifinvolv
capdepend
translat
machineri
produc
viral
protein
activ
host
protein
kinas
pkr
perk
hri
phosphoryl
attenu
translat
assembl
viral
particl
requir
host
cleavag
cov
spike
ifv
ha
golgi
apparatu
produc
viral
progeni
releas
bud
addit
nfkb
pathway
activ
inactiv
ikba
induc
proinflammatori
cytokin
ifn
innat
immun
respons
viral
infect
hostbas
pathway
target
repurpos
agent
control
viral
infect
repres
repurpos
drug
pink
background
green
thick
arrow
indic
induct
green
thick
stop
sign
indic
inhibit
scissor
sign
indic
proteolyt
cleavag
chotic
drug
treat
schizophrenia
cpz
identifi
screen
fdaapprov
drug
effect
inhibit
merscov
replic
low
micromolar
level
huh
cell
cpz
inhibit
merscov
replic
earli
postentri
stage
indic
abil
inhibit
earli
clathrinmedi
endocytosi
machineri
cpz
also
inhibit
sarscov
anim
coronavirus
ic
valu
mm
vero
cell
treatment
cell
cpz
significantli
reduc
entri
sarscov
cell
find
indic
cov
mainli
util
clathrinmedi
endocyt
pathway
enter
cell
amilorid
potassiumspar
diuret
use
treat
cardiovascular
diseas
block
epitheli
sodium
channel
within
distal
tubul
kidney
amilorid
deriv
nethylnisopropyl
amilorid
eipa
routin
use
specif
inhibit
macropinocyt
endocytosi
recent
report
reveal
combin
eipa
cpz
synergist
reduc
abil
ifva
infect
bovin
kidney
mdck
cell
indic
clathrinmedi
endocyt
macropinocyt
pathway
use
ifv
enter
cell
thu
combin
complementari
agent
need
develop
achiev
effect
control
viral
entri
host
cell
cellular
vacuolar
atpas
vatpas
locat
intracellular
organel
cytoplasm
membran
acidifi
late
endosom
pump
proton
across
endosom
membran
crucial
step
cov
ifv
entri
block
vatpas
activ
interfer
viral
infect
prevent
phdepend
membran
fusion
viral
envelop
endosom
membran
saliphenylhalamid
saliph
anticanc
compound
capabl
inhibit
vatpas
saliph
inhibit
acidif
endosom
reduc
product
progeni
virus
ic
valu
mm
ifvainfect
mdck
human
lung
adenocarcinoma
epitheli
cell
respect
administr
mice
mgkg
saliph
threetim
daili
day
result
surviv
rate
lethal
ifv
infect
mice
recov
day
pack
saliph
nanoparticl
enhanc
vitro
stabil
antivir
activ
low
cytotox
diphyllin
natur
compound
isol
cleistanthu
collinu
identifi
novel
vatpas
inhibitor
diphyllin
inhibit
endosom
acidif
human
osteoclast
reduc
vatpas
express
gastric
adenocarcinoma
cell
diphyllin
shown
effect
inhibit
ifv
infect
mdck
cell
ic
valu
rang
mm
diphyllin
also
effect
inhibit
clinic
isol
oseltamivirresist
ifvasan
strain
carri
drugresist
mutat
na
gene
amantadineresist
strain
diphyllin
well
toler
mice
deliveri
diphyllin
nanoparticl
increas
antivir
effect
felin
cov
also
well
toler
mice
niclosamid
salicylanilid
use
treat
parasit
helminth
infest
human
year
niclosamid
act
proton
carrier
target
acid
endosom
neutral
ph
coat
vesicl
synthet
liposom
niclosamid
effect
inhibit
ifva
cell
phdepend
sarscov
infect
amiodaron
antiarrhythm
agent
use
clinic
treat
supraventricular
ventricular
arrhythmia
amiodaron
inhibit
sarscov
infect
postendosom
stage
pretreat
amiodaron
result
reduct
viral
product
vero
cell
imatinib
inhibitor
nonreceptor
tyrosin
kinas
abelson
abl
involv
regul
cellular
pathway
cell
migrat
adhes
actin
reorgan
imatinib
use
anticanc
agent
reduc
cmlrelat
diseas
progress
death
imatinib
also
endosom
membran
fusion
inhibitor
capabl
inhibit
sarscov
merscov
infect
ec
valu
mm
respect
pretreat
imatinib
reduc
merscov
sarscov
product
vero
cell
safe
vero
cell
cc
valu
mm
howev
use
mg
imatinib
daili
myeloid
leukemia
patient
come
sideeffect
dizzi
blur
vision
somnol
fda
guid
administr
imatinib
mgkgday
result
statist
signific
reduct
longev
male
femal
respect
play
import
part
nonendosom
pathway
support
entri
virus
cell
assembl
viral
particl
cov
ifv
inhibit
nonendosom
camostat
nafamostat
result
suppress
cov
infect
inhibit
endosom
cathepsin
thu
cathepsin
promis
target
antivir
therapeut
develop
camostat
nafamostat
fdaapprov
drug
camostat
shown
exhibit
potent
antivir
activ
vitro
vivo
thu
logic
determin
efficaci
camostat
control
cov
ifv
clinic
studi
endosom
acidif
facilit
membran
fusion
endosom
virion
viral
entri
imatinib
fdaapprov
agent
inhibit
cov
fusion
endosom
membran
vitro
thu
vivo
efficaci
imatinib
control
viral
infect
need
determin
anim
model
treatment
anim
vatpas
inhibitor
saliph
diphyllin
reduc
acidif
suppress
viral
infect
pack
nanoparticl
help
increas
efficaci
inhibitor
control
viral
infect
toler
advers
effect
anim
thu
agent
promis
pursu
fda
approv
clinic
applic
control
viral
infect
viral
replic
util
host
cell
machineri
transcript
translat
signal
pathway
cell
cycl
accordingli
cellular
machineri
becom
target
develop
therapeut
drug
block
viral
replic
depict
fig
promis
drug
list
tabl
viral
replic
requir
pyrimidin
nucleotid
continu
biosynthesi
pyrimidin
pyrimidin
nucleosid
includ
uridin
cytidin
thymidin
dihydroorot
dehydrogenas
dhodh
dehydrogen
dihydroorot
orot
acid
key
step
biosynthesi
de
novo
pyrimidin
gener
uracil
bind
ribos
sugar
form
ribonucleosid
uridin
transcript
dhodh
inhibitor
teriflunomid
prodrug
leflunomid
brequinar
use
immunosuppress
agent
treat
rheumatoid
arthriti
multipl
sclerosi
patient
although
agent
show
abil
inhibit
de
novo
pyrimidin
synthesi
contribut
broadspectrum
antivir
activ
vitro
antivir
activ
ineffect
vivo
result
exogen
provid
uridin
bypass
inhibit
biosynthesi
pyrimidin
sustain
viral
repli
drug
discoveri
today
volum
number
march
cation
recent
studi
show
smallmolecul
capabl
inhibit
dhodh
effect
block
replic
variou
virus
arrest
cell
growth
suppli
exogen
deoxycytidin
sustain
cellular
dna
synthesi
rna
result
reduc
cytotox
without
reduc
inhibit
dengu
viru
denv
replic
thu
combin
use
deoxycytidin
provid
intrigu
strategi
reduc
cytotox
safe
use
dhodh
inhibitor
control
rna
virus
gemcitabin
fdaapprov
anticanc
agent
fluorouracil
analog
capabl
inhibit
pyrimidin
biosynthesi
although
gemcitabin
expect
interfer
pyrimidin
biosynthesi
viral
replic
gemcitabin
show
limit
antivir
abil
whether
gemcitabin
repurpos
control
viral
infect
remain
clarifi
protein
translat
process
consist
three
step
initi
elong
termin
initi
translat
eukaryot
ratelimit
step
protein
synthesi
involv
famili
eukaryot
initi
factor
eif
consist
recruit
small
ribosom
subunit
bind
gtp
residu
end
mrna
capdepend
translat
mani
virus
util
host
eif
initi
translat
phosphoryl
play
import
part
regul
initi
thu
eif
eif
phosphoryl
could
target
develop
antivir
agent
dsrnaactiv
protein
kinas
pkr
pkrlike
endoplasmicreticulumresid
protein
kinas
perk
phosphoryl
asubunit
respons
stress
lead
attenu
protein
synthesi
indomethacin
indo
inhibitor
routin
use
manag
inflamm
pain
clinic
indo
treatment
cell
activ
pkr
interferon
ifn
dsrnaindepend
manner
result
rapid
min
phosphoryl
termin
viral
translat
sarscovinfect
vero
cell
ic
valu
mm
indo
reduc
product
canin
cov
canin
adenocarcinoma
cell
ic
valu
mm
mm
indo
significantli
reduc
viral
product
cell
cc
mm
oral
administr
mgkg
indo
daili
day
reduc
product
canin
cov
dog
similarli
bioactiv
lipid
n
retinamid
fenretinid
use
control
cancer
reduc
denv
replic
induc
phosphoryl
oral
administr
mice
protect
mice
fulli
recov
denv
infect
safeti
bioavail
indo
clinic
determin
thu
compound
promis
candid
readi
repurpos
antivir
agent
addit
antiulc
drug
geranylgeranylaceton
gga
report
augment
express
pkr
gene
promot
phosphoryl
counteract
ifva
infect
gga
given
oral
everi
day
daili
dose
mgkg
result
reduct
mean
tumor
burden
compar
control
mice
group
mice
treat
oral
gga
mgkg
twice
daili
h
interv
complet
erad
viru
without
notabl
replic
within
day
accordingli
therapeut
induct
phosphoryl
promis
approach
develop
broadspectrum
antivir
agent
helicas
unwind
mrna
untransl
region
facilit
assembl
translat
preiniti
complex
silvestrol
natur
compound
isol
plant
aglaia
foveolata
inhibitor
silvestrol
shown
control
cancer
cell
vitro
vivo
silvestrol
inhibit
translat
replic
merscov
human
embryon
lung
fibroblast
cell
ec
valu
mm
respect
cov
use
capindepend
cisact
rna
intern
ribosom
entri
site
ire
element
viral
translat
also
inhibit
silvestrol
interestingli
silvestrol
exhibit
potent
modest
abil
inhibit
ifva
infect
cell
mdck
cell
respect
fail
inhibit
viral
infect
vero
cell
antivir
effect
silvestrol
ifv
infect
revers
drug
withdraw
result
rapid
dissolut
stall
preiniti
complex
stress
granul
resumpt
viral
protein
synthesi
inhibit
ifva
silvestrol
associ
cytotox
contrast
pateamin
irrevers
bind
result
extend
blockad
ifva
replic
drug
withdraw
inhibit
ifva
replic
mdck
vero
cell
minim
cytotox
find
indic
promis
target
therapeut
develop
inhibit
viral
translat
replic
agent
silvestrol
pateamin
kinaseinvolv
signal
pathway
wide
involv
regul
cellular
machineri
metabol
transcript
translat
cell
prolifer
differenti
death
among
other
studi
shown
erk
pathway
cyclindepend
kinas
cdk
essenti
viral
replic
cov
ifv
target
protein
kinas
signal
pathway
becom
focu
therapeut
develop
broadspectrum
antivir
agent
erk
pathway
mainli
mediat
intracellular
signal
membraneassoci
ra
cytoplasm
kinas
cascad
raf
mek
erk
erk
pathway
play
import
part
regul
gene
transcript
protein
translat
cell
death
cell
cycl
machineri
oncogen
mutat
braf
gene
frequent
detect
human
cancer
braf
inhibitor
vemurafenib
effect
inhibit
erk
pathway
approv
fda
treat
orbit
erdheimchest
diseas
ecd
vemurafenib
low
micromolar
level
inhibit
ifva
replic
reduct
via
suppress
viral
translat
interestingli
vemurafenib
also
inhibit
virusinduc
apoptosi
cell
via
suppress
apoptosisinduc
cytokin
raf
inhibitor
dabrafenib
sorafenib
fdaapprov
treat
cancer
raf
inhibitor
could
studi
repurpos
control
viral
infect
report
blockag
erk
pathway
limit
replic
cov
ifv
treatment
specif
inhibitor
suppress
earli
step
replic
mous
hepat
viru
mhv
variou
cell
line
treatment
cell
significantli
reduc
replic
ifva
nasal
administr
protect
mice
lethal
infect
ifva
without
develop
advers
effect
treatment
mice
mek
inhibitor
reduc
viral
product
lung
howev
low
bioavail
need
improv
effect
antivir
agent
inhibitor
trametinib
inhibitor
selumetinib
fdaapprov
anticanc
agent
effect
inhibit
merscov
infect
trametinib
also
inhibit
replic
variou
ifv
strain
vitro
vivo
interf
export
progeni
vrnp
nucleu
pretreat
trametinib
ec
mm
block
ifvinduc
cytopathogen
effect
decreas
viral
product
cell
oral
administr
mgkg
trametinib
mice
daili
effect
treat
rheumatoid
arthriti
oral
administr
mgkg
trametinib
daili
five
consecut
day
reduc
ifv
product
result
indic
applic
target
erk
pathway
develop
broadspectrum
therapeut
antivir
agent
cdk
famili
protein
kinas
activ
depend
interact
cyclin
famili
member
regul
cell
cycl
gene
transcript
rna
process
cell
surviv
cdk
requir
effici
replic
ifv
studi
show
interact
viral
rnadepend
rna
polymeras
rdrp
facilit
vrnp
associ
cellular
rna
polymeras
ii
pol
ii
viral
transcript
replic
recent
ht
human
kinas
inhibitor
librari
target
ifva
strain
cell
reveal
structur
divers
cellperm
compound
known
bioactiv
safeti
profil
among
compound
dinaciclib
inhibitor
flavopiridol
inhibitor
exhibit
potent
antivir
activ
variou
ifva
strain
without
detect
cytotox
dinaciclib
flavopiridol
current
undergo
clinic
trial
human
cancer
inhibitor
shown
inhibit
viral
gene
express
treatment
fulli
protect
mice
infect
contrast
mortal
untreat
mice
result
indic
develop
cdk
inhibitor
highli
promis
control
ifv
infect
polyamin
small
molecul
polyamin
carri
two
amino
group
polyamin
involv
conform
chang
dna
modul
transcript
translat
signal
pathway
cell
polyamin
shown
regul
transcript
translat
dna
rna
virus
difluoromethylornithin
dfmo
also
eflornithin
polyamin
inhibitor
approv
fda
treat
african
trypanosomiasi
cancer
dfmo
shown
reduc
viral
product
merscov
vero
cell
dfmo
need
studi
clarifi
vivo
toxic
efficaci
target
translat
indo
induc
phosphoryl
shown
inhibit
viral
replic
vitro
safe
protect
anim
viral
infect
indo
fdaapprov
control
inflamm
pain
target
signal
pathway
involv
cell
prolifer
block
erk
pathway
trametinib
inhibit
cdk
function
also
effect
control
viral
replic
vitro
protect
mice
viral
infect
trametinib
fdaapprov
treat
cancer
thu
indo
trametinib
clinic
studi
effici
repurpos
treat
viral
infect
agent
vemurafenib
gga
dinaciclib
flavopiridol
dfmo
combin
deoxycytidin
need
studi
reveal
abil
control
viral
infect
anim
model
accordingli
agent
target
translat
prolifer
signal
pathway
highli
promis
potenti
repurpos
broadspectrum
antivir
agent
host
innat
immun
system
capabl
recruit
immun
cell
pathogeninfect
site
cytokin
activ
adapt
immun
system
crucial
control
pathogen
infect
ifn
proinflammatori
cytokin
import
role
modul
innat
immun
respons
control
viral
infect
repurpos
drug
use
modul
innat
immun
system
fig
tabl
expect
therapeut
develop
produc
broadspectrum
antivir
agent
acceler
viral
infect
gener
highli
conserv
pathogenassoci
molecular
pattern
preferenti
activ
host
pattern
recognit
receptor
prr
result
activ
transcript
factor
induct
type
ifn
express
induct
canon
ikk
nfkb
activ
lead
product
proinflammatori
cytokin
ifn
produc
virusinfect
cell
bind
cellsurfac
ifn
receptor
ifnar
induc
upregul
hundr
ifnstimul
gene
product
isg
isg
shown
exhibit
wide
rang
antivir
abil
degrad
viral
nucleic
acid
inhibit
viral
gene
express
serv
prr
amplifi
ifn
signal
tradit
chines
medicin
drug
use
control
inflamm
cancer
pathogen
infect
thousand
year
herbal
medicin
shown
augment
type
ifn
respons
counteract
cov
ifv
infect
vitro
vivo
rupeston
acid
deriv
extract
artemisia
rupestri
l
inhibit
broad
spectrum
ifv
ifva
ifvb
oseltamivirresist
amantadineresist
ifv
strain
via
activ
heme
ifn
respons
treatment
reduc
viral
product
lung
mice
unabl
fulli
protect
mice
lethal
infect
possibl
result
ifn
suppress
viral
protein
activ
nfkb
hallmark
detect
viral
infect
nfkb
play
import
part
regul
gene
involv
inflamm
counteract
viral
infect
howev
ifva
take
advantag
nfkb
activ
via
degrad
ikb
viral
replic
thu
nfkb
could
target
interf
ifv
replic
saikosaponin
ssa
lipophil
triterpen
saponin
deriv
radix
bupleurum
antiinflammatori
immunomodulatori
properti
ssa
inhibit
nfkb
activ
effect
attenu
ifva
replic
ic
valu
mgml
strain
respect
cell
daili
subcutan
inject
ssa
mgkg
six
consecut
day
begin
h
postinfect
protect
mice
lethal
infect
ifva
treatment
mice
nfkb
inhibitor
caffeic
acid
phenethyl
ester
cape
andor
parthenolid
reduc
express
proinflammatori
cytokin
lung
significantli
increas
anim
surviv
sarscov
infect
proteasom
inhibitor
bortezomib
anticanc
drug
suppress
ikb
degrad
result
block
nfkb
activ
shown
noncytotox
level
mm
reduc
ifva
replic
three
order
magnitud
cell
howev
mm
becom
cytotox
thu
concern
antivir
activ
associ
cytotox
advers
effect
need
care
determin
develop
optim
antivir
agent
addit
stronger
neominophagen
c
snmc
glycyrrhizin
prepar
approv
japan
treat
chronic
hepat
diseas
glycyrrhizin
antioxid
antiinflammatori
immunomodulatori
antivir
agent
glycyrrhizin
suppress
ifva
replic
part
interfer
virusinduc
proinflammatori
gene
express
glycyrrhizin
suppress
sarscov
infect
earli
entri
late
replic
stage
vero
cell
ec
valu
mgml
andrographi
paniculata
antiinflammatori
antipyret
analges
antibacteri
hepatoprotect
agent
major
compon
dap
suppress
gene
express
proinflammatori
cytokin
chemokin
well
ifva
replic
result
suggest
antiinflammatori
agent
could
develop
therapeut
control
ifva
sarscov
infect
broadspectrum
antiparasit
drug
nitazoxanid
safe
drug
treat
intestin
infect
cryptosporidium
parvum
nitazoxanid
current
undergo
studi
control
viral
infect
nitazoxanid
interfer
posttransl
modif
ifv
hemagglutinin
human
anim
cell
ic
valu
rang
mgml
nitazoxanid
reportedli
effect
control
ifva
b
infect
phase
iii
clinic
studi
nitazoxanid
also
shown
inhibit
merscov
infect
mice
cell
ic
valu
mgml
suppress
express
viral
n
protein
proinflammatori
cytokin
interleukin
il
peripher
blood
mononuclear
cell
accordingli
nitazoxanid
regard
highli
promis
antivir
agent
repurpos
antiparasit
agent
lanthionin
synthetas
c
like
therapeut
target
treat
inflammatori
chronic
metabol
immunemedi
infecti
diseas
oral
administr
anim
mgkg
daili
day
reduc
mortal
induc
pandem
ifva
infect
interf
traffick
inflammatori
tissuedamag
cell
increas
cell
regulatori
macrophag
lung
manner
ligustrum
purpurascen
yc
yang
oleacea
ku
ding
cha
tea
use
antiinflammatori
antioxid
hepatoprotect
agent
ligustrum
purpurascen
extract
phenylethanoid
drug
discoveri
today
volum
number
march
review
glycosid
lpg
inhibit
ifva
replic
vitro
vivo
induc
ifng
oral
administr
mgkg
lpg
daili
day
protect
mice
lethal
infect
ifva
pandem
zoonot
ifv
strain
seriou
concern
public
health
particularli
popul
lack
preexist
immun
recent
develop
antivir
agent
modul
host
immun
respons
substanti
advanc
field
virolog
pharmaceut
well
significantli
contribut
healthcar
advanc
human
anim
lpg
shown
effect
control
ifva
infect
anim
activ
immun
respons
agent
consid
clinic
trial
treat
viral
infect
contrast
ssa
cape
glycyrrhizin
dap
undergo
vitro
vivo
studi
reveal
abil
control
viral
infect
howev
advers
effect
immunemodul
agent
need
serious
clarifi
develop
new
drug
take
year
cost
billion
us
dollar
approxim
oneinten
new
promis
preclin
drug
identifi
hundr
compound
might
approv
clinic
use
approxim
new
drug
fail
pass
safeti
protocol
clinic
trial
repurpos
fdaapprov
drug
timeeffici
costeffect
safe
approach
develop
therapeut
drug
new
indic
treat
viral
infect
repurpos
fdaapprov
drug
anticanc
agent
research
still
need
go
vitro
vivo
clinic
studi
determin
valu
candid
drug
treat
ifv
andor
cov
diseas
vitro
studi
identifi
viral
strain
target
determin
host
cell
rang
suscept
viral
infect
reveal
addit
molecular
target
specif
control
viral
infect
valu
host
molecular
target
evalu
gene
knockdown
knockout
mutat
via
method
rna
interfer
vivo
studi
determin
maxim
toler
dose
advers
effect
efficaci
control
viral
infect
pharmacokinet
drug
concentr
plasma
reestablish
effect
safe
regimen
protocol
treat
ifv
andor
cov
diseas
new
vitro
vivo
result
consid
exist
data
togeth
design
clinic
studi
viral
diseas
inevit
challeng
repurpos
drug
antivir
therapeut
gener
viral
infect
acut
pathogenesi
requir
higher
dose
repurpos
drug
dose
use
treat
origin
target
chronic
diseas
optim
outcom
thu
administr
rout
toxic
repurpos
drug
need
care
determin
viral
infect
also
result
chang
host
immun
system
also
function
host
organ
could
interfer
pharmacolog
effect
repurpos
drug
caus
addit
side
effect
thu
benefici
studi
combin
therapi
capabl
target
viral
compon
modul
cellular
machineri
allevi
advers
effect
achiev
optim
outcom
increas
antivir
efficaci
reduc
viral
resist
minim
toxic
side
effect
